Despite concerns about insufficient safety and efficacy data, legality, and cost, almost onethird of the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry respondents reported having tried non-prescription cannabis products in an attempt to alleviate their symptoms, according to a study published in the International Journal of MS Care. Amber Salter, PhD, MPH, and colleagues invited adult participants with MS from the NARCOMS Registry to complete a supplemental survey on cannabis use between March and April 2020. Participants reported cannabis use, treated symptoms, patterns, preferences, methods of use, and the factors limiting use. Of total respondents (N=3,249), 31% reported having ever used cannabis to treat MS symptoms, with 20% currently using cannabis. The remaining 69% had never used cannabis for MS symptoms, for reasons including not enough data about efficacy (40%), safety (27%), concerns about legality (25%), and cost (18%). The most common symptoms current users were attempting to treat were spasticity (80%), pain (69%), and sleep problems (61%).
